ACU Q2 2026 Earnings: EPS and Revenue Beat on MyMedic Acquisition

• Acme United reported Q2 2026 EPS of $1.22 and revenue of $62.7M, beating estimates due to a 16% sales increase driven by the MyMedic acquisition.
• The company highlighted gross margin improvement to 42.6% and expects continued recovery as tariff pressures ease through year-end.
• Management projects reaching $300 million in revenue within three years, supported by automation investments and D2C expansion.
• Investors should monitor risks including elevated SG&A expenses, currency headwinds, and uneven geographic performance, particularly in Canada.

Acme United Corporation delivered a robust financial performance for the second quarter of 2026, significantly exceeding market expectations across both top-line and bottom-line metrics. Earnings per share reached $1.22, surpassing the consensus forecast of $0.81 by a substantial margin. Revenue climbed to $62.7 million, beating estimates of $58.1 million and representing a 16% year-over-year increase. This strong performance was largely attributed to the successful integration of the MyMedic acquisition, which contributed significantly to the company's top-line growth. On an organic basis, excluding the impact of acquisitions, sales grew by 8%, indicating underlying strength in the core business. The market responded positively to these results, with the stock surging approximately 11.92% and nearing its 52-week high of $51.88.

A key driver of investor sentiment was the expansion of gross margins, which improved to 42.6% from 41.0% in the prior year period. Management attributes this margin recovery to a strategic inventory transition, where higher-cost, tariff-impacted stock is being replaced by lower-cost inventory. CEO Johnsen indicated that this margin recovery is expected to continue through the end of the year as the supply chain normalizes. The company is actively working to alleviate recent cost pressures by transitioning to lower-cost inventory, a process expected to conclude by year-end. Additionally, the MyMedic integration is progressing well, with a strategic focus on expanding distribution from direct-to-consumer channels into mass retail. The company anticipates strong profitability in Q4 driven by seasonal demand.

How Is Acme United Executing Its Strategic Growth Plan?

Acme United Corporation is executing a strategic growth plan centered on expanding its first aid and safety segment, which offers higher growth potential and recurring revenue compared to traditional cutting solutions. This shift is supported by recent acquisitions, notably MyMedic, which strengthens the company's direct-to-consumer capabilities and international footprint. Management has outlined an ambitious goal to reach $300 million in revenue within the next three years. To support this, the company is investing in automation and new product lines to improve operational efficiency and long-term margins. While the core cutting tools business remains a market leader under brands like Westcott and Clauss, the strategic emphasis is increasingly on high-growth medical and safety products.

The integration of MyMedic is a central pillar of this strategy, with efforts focused on expanding distribution beyond its current direct-to-consumer roots into mass retail channels. This expansion aims to enhance recurring revenue streams and broaden the company's market reach. The company also recently secured a new $65 million syndicated credit facility with HSBC to support ongoing operations and growth initiatives. These strategic moves are designed to balance core cutting tool leadership with higher-growth medical products, positioning Acme United for sustained long-term growth.

What Are the Key Risks and Market Headwinds?

Despite positive long-term outlooks, the company faces near-term headwinds from tariffs and inflation, which have impacted costs in previous quarters. However, management believes these pressures are easing. Recent financial disclosures highlight record sales and earnings in 2025, driven by strong first aid growth and successful acquisition integration. Investors should monitor risks including elevated SG&A expenses, currency headwinds, and uneven geographic performance. Geographic performance was uneven, with Canada lagging behind other regions.

The company faces ongoing challenges from tariff and freight costs, as well as currency headwinds. Geographic performance was uneven, with Canada lagging behind other regions. Despite these headwinds, the stock surged nearly 12% following the report, nearing its 52-week high of $51.88. The company also recently secured a new $65 million syndicated credit facility with HSBC to support ongoing operations and growth initiatives.

Looking ahead, management anticipates strong fourth-quarter profitability driven by seasonal demand. A key strategic focus remains the expansion of the MyMedic brand beyond its current direct-to-consumer model into mass retail channels. However, investors should note several risks. SG&A expenses remain elevated at 32% of sales, and the company faces ongoing challenges from tariff and freight costs, as well as currency headwinds. Geographic performance was uneven, with Canada lagging behind other regions. Despite these headwinds, the stock surged nearly 12% following the report, nearing its 52-week high of $51.88.

The company also recently secured a new $65 million syndicated credit facility with HSBC to support ongoing operations and growth initiatives.